Caregen FY 2025 Annual ReportBeta
Caregen annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 16, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Caregen FY 2025 Annual Report Analysis
Business Overview
- • Peptide and growth factor-based product sales to 130 countries, 97% export ratio in FY2025
- • MyoKi muscle loss prevention peptide gained FDA NDI approval in Feb 2025 after 3-month clinical trial on 80 subjects
Management Discussion & Analysis
- • 2025 revenue KRW 72.8B (-11.84% YoY, down KRW 9.78B), operating profit KRW 20.4B (-40.44%), net income KRW 20.1B (-37.80%)
- • Global medical esthetic segment sales decreased, causing revenue drop of KRW 9.7B; management cites reduced order volume from existing clients
Risk Factors
- • KRW 1.89B post-tax income and capital impact from 5% USD/KRW exchange rate movement in FY2025, up from KRW 1.58B
- • Largest FX exposure in USD assets: KRW 48.19B at FY2025-end, with USD liabilities KRW 0.42B
Caregen FY 2025 Key Financial MetricsDART
Total Assets
KRW 231.3B
▼ -3.9% YoY
Operating Cash Flow
KRW 18.6B
▲ +37.8% YoY
CapEx
KRW 3.9B
▼ -94.1% YoY
Source: KIFRS consolidated financial data from Caregen annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding